Caribou Biosciences Inc (CRBU) Stock Price, Quote & News

Company Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Ho...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 982 6030

Website: cariboubio.com

Address:

2929 7th Street, Suite 105, Berkeley, United States

Jidane Jul. 3 at 6:30 PM

$CRBU Moderna needs too much complicated system of manufacturing, still. It’s better than autologous ex-vivo in the perspective of cost, but not as cheap as other In-vivo Car-Ts.

0 · Reply

NicaInvest85 Jul. 3 at 5:41 PM

$CRBU $MRNA IS KILLING IT

0 · Reply

vu_jade Jul. 2 at 3:14 PM

$CABA $CCCC & $CRBU Back in the 3 pack of C’s for the revival!

2 · Reply

NewEarth Jul. 2 at 12:15 PM

$NTLA $PRME $CRBU $BEAM $REGN Hahahaha

0 · Reply

kule04 Jul. 2 at 10:56 AM

$CRBU

0 · Reply

cta7978 Jul. 1 at 8:05 PM

$CRBU

0 · Reply

Facade78 Jul. 1 at 4:09 PM

$CRBU Tik tak, where's Pfizer rofn ? Where is Rocrobio ? 🤣🤣

3 · Reply

STACKD0E Jun. 30 at 10:37 PM

$CRBU $AKTS 🙃✨️

0 · Reply

Perchprism1 Jun. 30 at 8:00 PM

$CRBU @elvisvandelay yeah, CRBU was added to Russell index, so accommodations were made.

0 · Reply

cta7978 Jun. 30 at 3:09 PM

$CRBU

0 · Reply

Caribou Biosciences Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 17, 2026, 10:30 AM EDT - 17 days ago

Caribou Biosciences Transcript: AGM 2026

2026-06-11T13:03:22.000Z - 23 days ago

Caribou Biosciences presents ANTLER trial results at EHA

Jun 11, 2026, 8:01 AM EDT - 23 days ago

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Jun 11, 2026, 8:00 AM EDT - 23 days ago

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Jun 10, 2026, 7:00 AM EDT - 24 days ago

Caribou Biosciences Slides: Corporate presentation

Jun 5, 2026, 8:00 AM EDT - 4 weeks ago

Caribou Biosciences Proxy statement: Proxy filing

Jun 4, 2026, 2:35 PM EDT - 4 weeks ago

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 5 weeks ago

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 19, 2026, 12:30 PM EDT - 6 weeks ago

Caribou Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 7 weeks ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 11:40 AM EDT - 7 weeks ago

Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 9:30 AM EDT - 7 weeks ago

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

2026-05-11T10:25:24.000Z - 7 weeks ago

Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright

May 7, 2026, 4:05 PM EDT - 2 months ago

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 7:00 AM EDT - 2 months ago

Caribou Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Caribou Biosciences Earnings release: Q1 2026

May 5, 2026, 4:05 PM EDT - 2 months ago

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

May 1, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Caribou Biosciences Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T12:14:17.000Z - 4 months ago

Caribou Biosciences price target raised to $13 from $11 at Evercore ISI

2026-03-05T21:28:29.000Z - 4 months ago

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

Mar 5, 2026, 4:05 PM EST - 4 months ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 3:00 PM EST - 4 months ago

Caribou Biosciences Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 4 months ago

Caribou Biosciences Earnings release: Q4 2025

Feb 19, 2026, 10:45 AM EST - 4 months ago

Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 17, 2026, 8:00 AM EST - 4 months ago

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 12, 2026, 4:05 PM EST - 5 months ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST - 5 months ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

2026-02-02T21:25:29.000Z - 5 months ago

Caribou Biosciences initiated with a Buy at Clear Street

2026-01-06T15:15:25.000Z - 6 months ago

Caribou Biosciences price target lowered to $6 from $8 at BofA

Dec 6, 2025, 7:30 AM EST - 7 months ago

Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2025, 7:00 AM EST - 7 months ago

Caribou Biosciences Slides: Corporate Presentation

Dec 2, 2025, 8:45 AM EST - 7 months ago

Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 4:05 PM EST - 7 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

2025-11-12T22:25:13.000Z - 8 months ago

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Nov 12, 2025, 4:05 PM EST - 8 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

Caribou Biosciences Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Caribou Biosciences Quarterly report: Q3 2025

2025-11-05T11:21:02.000Z - 8 months ago

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

2025-11-03T15:15:34.000Z - 8 months ago

Caribou Biosciences price target raised to $8 from $5 at Citi

Nov 3, 2025, 8:00 AM EST - 8 months ago

Caribou Biosciences Transcript: Study Result

Nov 3, 2025, 8:00 AM EST - 8 months ago

Caribou Biosciences Press release: Study Result

Nov 3, 2025, 8:00 AM EST - 8 months ago

Caribou Biosciences Slides: Study Result

2025-11-03T12:22:51.000Z - 8 months ago

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

2025-11-03T12:15:12.000Z - 8 months ago

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

Nov 3, 2025, 7:00 AM EST - 8 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 8 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 2, 2025, 4:00 PM EST - 8 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Sep 3, 2025, 2:30 PM EDT - 10 months ago

Caribou Biosciences Transcript: Citi's Biopharma Back to School Conference

Aug 30, 2025, 7:00 AM EDT - 11 months ago

Caribou Biosciences Slides: Corporate Presentation

Aug 25, 2025, 4:05 PM EDT - 11 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

2025-08-12T21:00:25.000Z - 11 months ago

Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

Aug 12, 2025, 4:05 PM EDT - 11 months ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Caribou Biosciences Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Caribou Biosciences Quarterly report: Q2 2025

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 13, 2025, 5:35 PM EDT - 1 year ago

Caribou Biosciences Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Registration statement: Registration Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

May 6, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Jidane Jul. 3 at 6:30 PM

$CRBU Moderna needs too much complicated system of manufacturing, still. It’s better than autologous ex-vivo in the perspective of cost, but not as cheap as other In-vivo Car-Ts.

0 · Reply

NicaInvest85 Jul. 3 at 5:41 PM

$CRBU $MRNA IS KILLING IT

0 · Reply

vu_jade Jul. 2 at 3:14 PM

$CABA $CCCC & $CRBU Back in the 3 pack of C’s for the revival!

2 · Reply

NewEarth Jul. 2 at 12:15 PM

$NTLA $PRME $CRBU $BEAM $REGN Hahahaha

0 · Reply

kule04 Jul. 2 at 10:56 AM

$CRBU

0 · Reply

cta7978 Jul. 1 at 8:05 PM

$CRBU

0 · Reply

Facade78 Jul. 1 at 4:09 PM

$CRBU Tik tak, where's Pfizer rofn ? Where is Rocrobio ? 🤣🤣

3 · Reply

STACKD0E Jun. 30 at 10:37 PM

$CRBU $AKTS 🙃✨️

0 · Reply

Perchprism1 Jun. 30 at 8:00 PM

$CRBU @elvisvandelay yeah, CRBU was added to Russell index, so accommodations were made.

0 · Reply

cta7978 Jun. 30 at 3:09 PM

$CRBU

0 · Reply

vu_jade Jun. 30 at 1:14 PM

$CCCC $CRBU $CABA rounding back into position

0 · Reply

cta7978 Jun. 29 at 6:12 PM

$CRBU Someone bought Jan 2027 $2.5 calls (LEAPs, ~19 months out) at $0.30 for 2,550 contracts for $76,500 premium.

3 · Reply

deaccord Jun. 29 at 4:12 PM

$CRBU Shorts getting nervous, how to cover when there are so few shares

0 · Reply

elvisvandelay Jun. 29 at 3:53 PM

$CRBU massive volume yesterday, anyone know whats up with that?

0 · Reply

Nitro111 Jun. 26 at 8:41 PM

$CRBU so is $PFE buying this or what? ⌛

1 · Reply

smallcapexpert Jun. 26 at 5:20 PM

$CRBU I’m in this one 1,66$ avg, huge potential and ready for a 3$ squeeze 📈

1 · Reply

Perchprism1 Jun. 26 at 1:32 PM

$CRBU according to Google AI, there will be greater volume today, but price will subside Monday as retail buyers get over disappointment from Pfizer taking a pass regarding their ROFN, which expires Sunday.

1 · Reply

cta7978 Jun. 25 at 7:50 PM

$CRBU (Caribou Biosciences) is on the preliminary additions list for the Russell 3000 Index (and likely the Russell 2000 as a small-cap biotech name) as part of the June 2026 semi-annual reconstitution. Changes take effect after the market close on Friday, June 26, 2026 (tomorrow), with the new index composition applying from Monday, June 29.

0 · Reply

Windytimes Jun. 25 at 7:43 PM

$CRBU fuk it to zero or moon!!!

1 · Reply

HughGeez Jun. 25 at 2:46 AM

$CRBU $SPCX

1 · Reply

cta7978 Jun. 24 at 3:58 PM

$CRBU

0 · Reply

HughGeez Jun. 24 at 2:15 PM

$CRBU

0 · Reply

Market Cap	180.51M
Revenue (ttm)	11.16M
Net Income (ttm)	-148.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,327.33%
Debt to Equity Ratio	0.00

Volume	1,868,900
Avg Vol	2,010,564
Day's Range	N/A - N/A
Shares Out	99.18M
Stochastic %K	72%
Beta	2.36
Analysts	Strong Sell
Price Target	$12.00